Coronary artery disease
Conditions
Interventions
caFFR group:The degree of myocardial ischemia was measured using coronary angiographic flow reserve fraction,thus the diagnosis and treatment plan was given
Control group:Diagnosis and treatment plan was determined based on the results of angiography
Sponsors
The University of Hong Kong- Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.For patients with stable or unstable angina pectoris, coronary angiography can be performed; 2.Coronary artery lesion diameter stenosis of 30%-90%. 3.Aged 18 or above, gender unlimited; 4.Intensive angiography is considered necessary and feasible, with PCI if necessary; 5.Non-convict vascular assessment of patients with suspected coronary heart disease and acute non-ST-elevation; myocardial infarction, and non-convict vascular assessment of patients with previous ST-elevation myocardial infarction; 6.Subjects volunteered to participate in the clinical trial and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart disease; 2. Congenital heart disease; 3 Patients with prior CABG or treatment with chronic obstructive vascular predisposition to CABG; 4. Patients lost to follow-up without follow-up; 5. Acute ST-segment elevation myocardial infarction within 6 days; 6. Cardiogenic shock or left ventricular ejection fraction <= 50%; 7. EGFR < 30ml/min(1.73m2); 8. Patients with severe coagulation dysfunction or hemorrhagic diseases; 9. People who are allergic to iodine contrast agent or adenosine and adenosine is not suitable for them; 10. Subsequent plans for heart valve or aortic surgery; 11. Expected survival of less than 1 year; 12. Women who are pregnant or who plan to become pregnant in the near future; 13. The subject has participated in or is participating in the clinical trial of any other device or drug within the last 1 month; 14. The investigator believes that there are other conditions in the subjects that are not suitable for the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MACE; | — |
Secondary
| Measure | Time frame |
|---|---|
| The composite end point was all-cause death, myocardial infarction (excluding perioperative MI), and unplanned revascularization;Cardiovascular, non-cardiovascular, and undetermined deaths;Target vascular-related and non-target vascular-related MI;Target vessel revascularization (TVR);Any coronary revascularization;Clear and possible stent thrombosis;Evaluation of health economics;Analysis of subjects' discomfort during the examination; | — |
Countries
China
Contacts
Public ContactKai Hang Yiu
The University of Hong Kong - Shenzhen Hospital
Outcome results
None listed